Coal-Workers’ Pneumoconiosis Drug Market Trends by Key Players, End User, Demand, Analysis Growth and Forecast 2028

  • Increasing prevalence of black lung disease is driving the market growth
  • Increasing mining activities is boosting the market growth
  • Increasing research and development expenses is accelerating the market growth
  • Rising healthcare expenditures is also enhancing the market growth
  • Lack of awareness amongst coal-workers is hindering the market growth
  • Limited availability of medicinal treatment options is restraining the market growth
  • High cost of surgery mainly the lung transplantation is hampering the market growth
  • In March 2019, AstraZeneca received Orphan Drug designation from The U.S FDA for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease. This designation enables the company to receive financial incentives such as an extended period of exclusivity
  • In March 2018, Boehringer Ingelheim International GmbH received Fast Track designation from the U.S FDA for nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). This designation will help the company for the early approval of nintedanid

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
DataBridge Market Research

DataBridge Market Research

28 Followers

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approach